What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
His main research concerns Internal medicine, Oncology, Glioma, Surgery and Temozolomide.
Within one scientific family, David A. Reardon focuses on topics pertaining to Gastroenterology under Internal medicine, and may sometimes address concerns connected to Regimen and Gliosarcoma.
His Oncology research is multidisciplinary, incorporating perspectives in Cancer, Cilengitide, Nivolumab, Radiation therapy and Pharmacology.
His Glioma research includes elements of Salvage therapy, Central nervous system disease and Pathology.
His work deals with themes such as Adverse effect and Clinical trial, which intersect with Surgery.
His research integrates issues of Immunology, O6-Benzylguanine, Chemoradiotherapy and Dacarbazine in his study of Temozolomide.
His most cited work include:
- IDH1 and IDH2 Mutations in Gliomas (3746 citations)
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group (2349 citations)
- Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme (1184 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Internal medicine, Oncology, Bevacizumab, Glioma and Temozolomide.
His studies in Internal medicine integrate themes in fields like Surgery and Glioblastoma.
His study in Oncology is interdisciplinary in nature, drawing from both Cancer, Chemotherapy, Clinical endpoint, Recurrent glioblastoma and Pharmacology.
The study incorporates disciplines such as Angiogenesis, Progression-free survival, Irinotecan, Vascular endothelial growth factor and Nivolumab in addition to Bevacizumab.
His Glioma study combines topics from a wide range of disciplines, such as Pharmacokinetics, Toxicity and Pathology.
The various areas that David A. Reardon examines in his Temozolomide study include Adverse effect and Dacarbazine.
He most often published in these fields:
- Internal medicine (57.75%)
- Oncology (48.48%)
- Bevacizumab (29.18%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (57.75%)
- Oncology (48.48%)
- Glioblastoma (19.60%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Internal medicine, Oncology, Glioblastoma, Cancer research and Bevacizumab.
In most of his Internal medicine studies, his work intersects topics such as Glioma.
His Glioma study combines topics in areas such as Mutant and Pathology.
He has researched Oncology in several fields, including Cancer, Survival rate, Temozolomide, Nivolumab and Recurrent glioblastoma.
As part of one scientific family, David A. Reardon deals mainly with the area of Glioblastoma, narrowing it down to issues related to the Newly diagnosed, and often Radiation therapy.
The Cancer research study combines topics in areas such as Receptor and Immune system, Immunotherapy.
Between 2017 and 2021, his most popular works were:
- Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. (445 citations)
- Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial (356 citations)
- Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. (309 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
David A. Reardon spends much of his time researching Internal medicine, Oncology, Cancer research, Clinical trial and Bevacizumab.
His study brings together the fields of Glioma and Internal medicine.
His research in Oncology intersects with topics in Survival rate, Cancer and Glioblastoma, Temozolomide.
His Cancer research research incorporates elements of T cell, Immune system, Immunotherapy and PI3K/AKT/mTOR pathway.
His work carried out in the field of Clinical trial brings together such families of science as Isocitrate dehydrogenase, Neurologic Oncology, Response assessment and Intensive care medicine.
His Bevacizumab study incorporates themes from Pembrolizumab, Phases of clinical research, Vascular endothelial growth factor, Combination therapy and Biomarker.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
